Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Gyan

Showing results (161-170 of 174) with videos related to

Pageof 18
Sort By:
Haematologica|October 6, 2018
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromesSophie Park, Olivier Kosmider, Frédéric Maloisel, et al.
Science Translational Medicine|July 12, 2019
A variant erythroferrone disrupts iron homeostasis in <i>SF3B1</i>-mutated myelodysplastic syndromeSabrina Bondu, Anne-Sophie Alary, Carine Lefèvre, et al.
Bulletin Du Cancer|September 12, 2024
[Nurturing and growing a community of department heads: Act 2 in haematology]Roch Houot, Claire Calmettes, Sophie Park, et al.
Blood|January 29, 2021
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHLNorbert Schmitz, Lorenz Truemper, Krimo Bouabdallah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS StudyCaroline Houillier, Luc Taillandier, Sylvain Dureau, et al.
The New England Journal of Medicine|November 9, 2007
Chemotherapy plus involved-field radiation in early-stage Hodgkin's diseaseChristophe Fermé, Houchingue Eghbali, Jacobus H Meerwaldt, et al.
European Journal of Haematology|March 25, 2021
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trialAnne Bouvier, Jean-François Hamel, Jacques Delaunay, et al.
Blood Advances|August 4, 2025
Brentuximab Vedotin addition to Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphoma: a LYSA Phase II StudyOlivier Tournilhac, Krimo Bouabdallah, Solene Lecolant, et al.
Haematologica|February 22, 2024
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphomaAnastasios Stathis, Maria Cristina Pirosa, Lorella Orsucci, et al.
American Journal of Hematology|April 17, 2021
Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network studyMarion Lam, Valérie Touitou, Sylvain Choquet, et al.
Pageof 18

Showing results (161-170 of 174) with videos related to

Sort By:
Pageof 18
Haematologica|October 6, 2018
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromesSophie Park, Olivier Kosmider, Frédéric Maloisel, et al.
Science Translational Medicine|July 12, 2019
A variant erythroferrone disrupts iron homeostasis in <i>SF3B1</i>-mutated myelodysplastic syndromeSabrina Bondu, Anne-Sophie Alary, Carine Lefèvre, et al.
Bulletin Du Cancer|September 12, 2024
[Nurturing and growing a community of department heads: Act 2 in haematology]Roch Houot, Claire Calmettes, Sophie Park, et al.
Blood|January 29, 2021
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHLNorbert Schmitz, Lorenz Truemper, Krimo Bouabdallah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS StudyCaroline Houillier, Luc Taillandier, Sylvain Dureau, et al.
The New England Journal of Medicine|November 9, 2007
Chemotherapy plus involved-field radiation in early-stage Hodgkin's diseaseChristophe Fermé, Houchingue Eghbali, Jacobus H Meerwaldt, et al.
European Journal of Haematology|March 25, 2021
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trialAnne Bouvier, Jean-François Hamel, Jacques Delaunay, et al.
Blood Advances|August 4, 2025
Brentuximab Vedotin addition to Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphoma: a LYSA Phase II StudyOlivier Tournilhac, Krimo Bouabdallah, Solene Lecolant, et al.
Haematologica|February 22, 2024
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphomaAnastasios Stathis, Maria Cristina Pirosa, Lorella Orsucci, et al.
American Journal of Hematology|April 17, 2021
Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network studyMarion Lam, Valérie Touitou, Sylvain Choquet, et al.
Pageof 18